Today's Date: April 17, 2021
New Invention Stops Costly Snags with Face Mask Strings   •     STI Awareness Month: Rachel Zar, Relationship and Sex Therapist on Staying Safe Between the Sheets   •   Boutique Air Announces New Las Vegas-Merced Route   •   Government of Canada COVID-19 Update for Indigenous Peoples and communities   •   Global COVID-19 Vaccine Inequalities Are Scandalous, Says AHF   •   Franklin Covey Co. Named to 2021 Training Industry Top 20 Training Companies List For 10th Time For Best-in-Class Leadership Sol   •   Wrangler® Unveils Global Sustainability Platform: WeCare Wrangler™   •   Citizens for a Pro-Business Delaware Joins Pastor Hackett's Protest for Diversity on Chancery Court   •   Cymbiotika Launches Mother’s Day Bundle   •   Wildflower Strengthens Commitment to Black Maternal Health with New Tools, Resources for Black Mothers   •   /C O R R E C T I O N -- SWAIA/Santa Fe Indian Market/   •   USA Fashion to Manufacture a Collection of Solid Basic Apparel as a Core Offering of its USA Fashion Women’s Clothing Bran   •   Make Reading Part of Your Mother's Day Celebration   •   Reynolds Consumer Products Inc. to Report First Quarter 2021 Financial Results on May 5, 2021   •   Biden administration forces taxpayers to fund the trafficking of aborted baby body parts, says Family Research Council   •   Half of Kids with Inflammatory Syndrome After COVID-19 Have Neurologic Symptoms   •   Health Foundation of South Florida, Miami-Dade and Broward counties partner to launch locally produced, multi-media COVID vaccin   •   Labcorp to Webcast Its Annual Meeting of Shareholders   •   One Voice Children's Choir Uses Their Voices to Raise Awareness of Their Nonprofit with "Little Voice"   •   CUPE Lays Out Priorities for Budget 2021
Bookmark and Share

Femtech startup OCON Healthcare announces last patient in phase IIa clinical study, evaluating its intrauterine drug delivery pl

Femtech startup OCON Healthcare announces last patient in phase IIa clinical study, evaluating its intrauterine drug delivery platform IUB™ SEAD™, a non-invasive treatment for abnormal uterine bleeding (AUB)

The trial assesses the safety and efficacy of the IUB™ SEAD™, a disruptive treatment for AUB. In this study, 50% of the participating patients have reached the End of the Study point, demonstrating a significant reduction in bleeding, avoiding the need to undergo invasive uterine ablation procedures or even a hysterectomy

PR Newswire

MODIIN, Israel, March 4, 2021 /PRNewswire/ -- OCON Healthcare, a women's health company which develops, manufactures and commercializes an innovative 3D intrauterine drug delivery technology based on its patented IUBTM (Intra Uterine Ball) platform, today announced it had completed enrollment of its Phase IIa clinical study evaluating its intrauterine drug delivery platform IUB™ SEAD™,a non-invasive treatment for abnormal uterine bleeding (AUB).

AUB is a medical condition affecting nearly 1 out of 4 women in the reproductive age range (18-50), causing heavy irregular bleeding from the uterus resulting in a significant decrease in their quality of life and even risk of death.

OCON's IUB™ SEAD™ is a disruptive non-invasive treatment for AUB, designed as an alternative to the traditional hormonal medication and/or aggressive and irreversible ablation procedures that are non-reversible and remove the women's chances for later pregnancy, or hysterectomy procedures.

In this clinical study, held in 3 medical centers in Europe, 8 out of the participating 16 patients have reached the End of the Study point, and demonstrated a significant reduction in bleeding. No safety issues were reported to date and all patients were discharged with no complaints. A follow up duration of 12 months is made for each patient post procedure.

"More women and doctors are looking today for innovative and simple solutions to treat AUB," said Prof. Sergio Haimovich, Chief Medical Officer at OCON Healthcare. "The IUB™ SEAD™ solves this medical condition, which negatively impacts the health and the quality of life of 25% of all women in their reproductive years,  with no need for irreversible ablation techniques or hysteractomies. This ground breaking technology already made a positive impact on womens lives and we are certain we will see more of it during our clinical studies in the near future."

As far as the OCON is aware, the global AUB surgery market is expected to reach $1.3 billion by 2024, with 1.4 million women per year who report AUB.

CONTACT

Ravit Levrann

ravit@theinvestor.co.il

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/femtech-startup-ocon-healthcare-announces-last-patient-in-phase-iia-clinical-study-evaluating-its-intrauterine-drug-delivery-platform-iub-sead-a-non-invasive-treatment-for-abnormal-uterine-bleeding-aub-301240430.html

SOURCE OCON Healthcare



Back to top
| Back to home page
Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
Breaking News
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News